View : 79 Download: 0

Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System

Title
Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System
Authors
Jung, Ki SunKim, Yoo-JinKim, Yeo-KyeoungPark, Sung KyuKim, Hoon GuKim, Soo JeongPark, JinnyChoi, Chul WonDo, Young RokKim, InhoPark, SeonyangMun, Yeung-ChulJeong, Seong HyunKim, Min-KyoungYi, Hyeon GyuChang, Myung HeeKim, Su YounLee, Je-HwanJang, Jun Ho
Ewha Authors
문영철
SCOPUS Author ID
문영철scopus
Issue Date
2019
Journal Title
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
ISSN
2152-2650JCR Link

2152-2669JCR Link
Citation
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA vol. 19, no. 10, pp. 656 - 664
Keywords
DecitabineIPSSLower-Risk Prognostic Scoring SystemLR-PSSMyelodysplastic syndrome
Publisher
CIG MEDIA GROUP, LP
Indexed
SCIE WOS
Document Type
Article
Abstract
Decitabine showed a survival benefit in the higher-risk group (Lower-Risk Prognostic Scoring System [LR-PSS] category 3) of the International Prognostic Scoring System (IPSS) lower-risk (IPSS low or intermediate-1) myelodysplastic syndrome patients who responded to decitabine. Therefore, classification using the LR-PSS category was helpful for this subgroup, indicating that decitabine treatment might alter the natural course of disease in these patients. Introduction: Decitabine has shown clinical benefits in patients with intermediate (INT)-2 or high-risk myelodysplastic syndrome (MDS), determined according to the International Prognostic Scoring System (IPSS), but the benefits have not been well demonstrated in patients with lower-risk (IPSS low or INT-1) disease. Recently, it was proposed that the prognosis for patients with IPSS lower-risk disease is heterogeneous, with a substantial proportion of these patients having poor survival. Patients and Methods: This study included patients with IPSS lower-risk MDS from the DRAMA (An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome; NCT01400633) and DIVA (A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome; NCT01041846) studies, which were prospective observational studies on the efficacy and safety of decitabine treatment in patients with MDS. Using the Lower-Risk Prognostic Scoring System [LR-PSS], we classified IPSS lower-risk MDS. Patients in each LR-PSS category were divided according to overall response (OR) to decitabine treatment, and survival outcomes were compared. Results: One hundred sixteen patients were enrolled: LR-PSS category 1 (n = 12; 10.3%), category 2 (n = 56; 48.3%), and category 3 (n = 48; 41.4%). Survival outcomes differed among the 3 categories (P = .046). The overall survival according to OR showed a significant difference in total patients (P = .008) and category 3 patients (P = .003). We analyzed predictive factors for OR, but no variable was found to significantly affect OR. Conclusion: Decitabine treatment showed a survival benefit in the higher-risk group of IPSS lower-risk MDS patients who responded to treatment, and classification using the LR-PSS category was helpful for this subgroup, indicating that decitabine treatment might alter the natural course of disease in these patients.
DOI
10.1016/j.clml.2019.06.003
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE